

PRODUCT DATA SHEET

Liquid Biopsy Sequencing

LIQUID BIOPSY SEQUENCING

Genomic profiling of cell free tumor DNA (Liquid Biopsy) offers the potential to revolutionize cancer precision medicine. As a proxy for tumor tissue profiling, successful liquid biopsy analysis can help select appropriate patients for clinical trials, provide useful data for treatment monitoring, and discover genomic mechanisms of disease resistance.

CLINICAL RESEARCH

Broad Genomic Service's Liquid Biopsy sequencing combines the rapid turnaround time needed for clinical applications with considerable flexibility and scale ideal for research. From a single liquid biopsy sample, we provide ultra-low pass whole genome sequencing (ULPWGS) data combined with deeper coverage of your choosing.

ULPWGS information is perfect for screening purposes, and allows for informed decision making as to what additional breadth and depth of coverage suits your research aims, be it; whole exome, pan-cancer panel or custom panel sequencing.

INPUT REQUIREMENTS

5-10ml Blood, 4-6ml plasma, or 5-50ng cfDNA

OUTPUTS / DELIVERABLES

- BAM file with data from ultra-low pass whole genome with 0.1x-0.3x coverage
- Copy Number
- Tumor Fraction & Ploidy Analysis


Greater breadth and depth of coverage than other liquid biopsy services

Designed with clinical research in mind

ADDITIONAL INFORMATION

- ~30 day TAT from sample receipt to ULPWGS data delivery
- Samples with a tumor purity >10% should proceed into the exome workflow, samples <10% are more suited for a custom panel
- Read lengths for all library types, ULP, exome and custom panel are 2x151bp
- Specific deliverables for Exome, Pan-Cancer Panel and Custom Panel can be found online

FLEXIBILITY OF THE WORKFLOW



GENOMIC SERVICES

FOR MORE INFORMATION

Web: genomics.broadinstitute.org

Email: genomics@broadinstitute.org